201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Market cap: $707.2M (12/18/2025)
Price: $33.33
Other Events
Bylaw Amendments Approved by Lyell Immunopharma Board on December 3, 2025
Reports Business Highlights and Financial Results for the Third Quarter 2025
Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lynn Seely Appointed Interim Principal Financial Officer at Lyell Immunopharma
Changes in Board, Management or Compensation
Earnings Release
Announces up to $100 Million Equity Private Placement
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
SEC Staff Correspondence
Correspondence